Release Date: December 23, 2025
Expiration Date: December 23, 2026
Activity Overview
Sickle cell disease (SCD) remains a complex, high-burden condition that significantly impacts patients across every stage of life. This educational program brings together leading clinical experts to provide a comprehensive examination of the physical, psychosocial, and healthcare-system challenges faced by individuals living with SCD. Drawing on decades of collective experience, faculty will review current epidemiology, the persistently high rates of acute and chronic complications, and the substantial morbidity associated with pain, organ damage, and reduced quality of life. Faculty will also interpret data through the lens of real-world clinical practice so that participants clinicians gain a deeper understanding of the lived experience of patients, the clinical complexities that challenge optimal care, and opportunities to improve outcomes across the continuum of SCD management.
Target Audience
This educational activity is primarily directed toward hematologists, NPs, and PAs. Other clinicians involved in the care of SCD will also be invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Outline the burden of disease for patients with SCD
Matthew Heeney, MD
Associate Chief, Hematology
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, MA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Agios, Beam Therapeutics, Blueprint Medicines, Novartis, Novo Nordisk, Octapharma, Omeros, Pfizer, Sanofi; Grant/Research Funding: Agios, Beam Therapeutics, Novartis
Biree Andemariam, MD
Professor of Medicine
Director, New England Sickle Cell Institute
Director, Connecticut Bleeding Disorders Center
University of Connecticut Health
Farmington, CT
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Afimmune, Agios, Beam Therapeutics, bluebird bio, Bristol Myers Squibb, Chiesi, Editas, Fulcrum, Hemanext, Novo Nordisk, Octapharma, Pfizer, Roche, Sanofi, Vertex; Grant/Research Funding: Afimmune, Agios, Hemanext, Novo Nordisk, Pfizer
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here